Cecilia Pessoa Gingerich

Overall antibiotic prescriptions have dropped, but short-term postoperative prescriptions have increased in recent years.

This is the first generic approval of the tablet form of vigabatrin, which is indicated for treating focal seizures in patients with epilepsy.

Currently in phase 1 testing, ACX-362E is being developed as a narrow spectrum antibiotic for the treatment of Clostridium difficile infection.

The Amplatzer Piccolo Occluder is implanted via catheter to repair patent ductus arteriosus in newborns weighing as little as 2 pounds.

A pilot study testing a multi-tasking game in children with autism and ADHD demonstrated feasibility, acceptability, and non-significant efficacy.

Patients treated with SAGE-217 had significantly improved depression scores and were more likely to achieve remission than those receiving placebo.

Medical students’ perceptions of the barriers to applying for a dermatology residency vary based on race, ethnicity, and socioeconomic background.

The FDA has expanded approval for the Embrace smartband to be used by children aged 6 years and older with epilepsy.

Crizanlizumab is being developed to prevent painful and unpredictable vaso-occlusive crises in patients with sickle cell disease.

The FDA has approved 2 new dosages of the pain reliever that combines benzhydrocodone and acetaminophen.

The WEB Aneurysm Embolization System is designed to treat intracranial wide neck bifurcation aneurysms.

This past year came with a multitude of new FDA approvals for antiretroviral therapies as well as research highlighting HIV and various comorbidities.

For patients with chronic liver disease, opioid prescriptions are common, and high-risk prescriptions are associated with hepatic decompensation, especially ascites.

The guidance touches on hand hygiene, airway management, environmental disinfection, and IV drug injection recommendations.

ALD-related hospitalizations grew from 2008 to 2014, especially among women, Asians, Hispanics, and people 50 to 69 years of age.

In a clinical trial, the reSET-O app increased retention in an outpatient opioid use disorder treatment program.

Investigator Anita Clayton, MD, shares insights into the new vortioxetine data and its implications for patients with depression and treatment-emergent sexual dysfunction.

The Spiration Valve System treats emphysema by blocking air from entering diseased areas of the lung.

Can we learn from the last flu season and prepare for the coming peak influenza activity of the current season?

The FDA has approved Dextenza, a dexamethasone ophthalmic insert, for the treatment of ocular pain following ophthalmic surgery.

Ravulizumab dosed every 8 weeks was noninferior to eculizumab given every 2 weeks, but the treatment did not achieve superiority.

The FDA has accepted a Biologics License Application as well as granted Priority Review for the gene therapy that treats spinal muscular atrophy (SMA) Type 1.

While common in adults, congenital cytomegalovirus may cause problems such as hearing and vision loss in newborns.

Wiviott, senior investigator of the DECLARE-TIMI 58 trial, says that SGLT2 inhibitors and GLP-1 receptor agonists are changing the paradigm of how clinicians manage diabetes and cardiovascular risk.

The 4th generation VITROS HIV Combo test has been approved for use with the VITROS ECi/ECiQ Immunodiagnostic System.

Topline data shows that the diabetes medication is non-inferior to placebo with regard to a composite outcome of major adverse cardiovascular events.

Many trials for monoclonal antibody therapies for asthma reported small percentages of African American or Hispanic participants, and some didn’t report racial/ethnic demographics at all.

Jay Edelberg, MD, PhD, of Sanofi and Robert Sanchez, PhD, of Regeneron shared about the recent ODYSSEY OUTCOMES trial of alirocumab (Praluent) and accompanying cost-effectiveness study.

Emapalumab-lzsg was approved by the FDA for the treatment of primary hemophagocytic lymphohistiocytosis in pediatric and adult patients with refractory, recurrent, or progressive disease, or intolerance to conventional therapy.

Emapalumab (Gamifant) is the first FDA-approved treatment for a rare condition that causes life-threatening hyper-inflammation.